Beijing Studies: Infected Omikons original strains, they will still be infected

(Reuters in New York) A new study found that people who have been infected with the primitive strains of Omikon, even if they have vaccinated the vaccine and additional agent, may still be infected with other subtypes of Omikdon.

Peking University Biomedical Frontier Innovation Center, Peking University School of Life Sciences, and Beijing Changping Labs and other institutions jointly conducted research, and issued reports at the authoritative British Science Journal Nature (Nature) on Friday.The results showed that the antibodies produced by the vaccine and infected with the Omikon BA.1 can neutralize the Omikon BA.1 and the primitive strain.However, genetic mutations have occurred in Omikon subtypes that are currently spread and have the ability to avoid antibodies.

Researchers found through test tube experiments that the newer subtypes focus on avoiding the antibodies produced after the original strain and vaccination.

Research warning, according to the vaccine addition agent developed by the Omikon BA.1 strain, such as Pfizer and Modner, it may not be able to play a wide range of protective effects on other new strains of Omikon.

Experiments show that the monoclonal antibody drugs produced by Lilly Company, Bebtelovimab, and the Cilgavimab contained in Evushel, produced by Astrikon, can still be effectively neutralized and neutralize.Omikon BA.5, BA.4 and BA.2.12.1 strains.

The microorganism and infectious disease researcher Garcia -Sastre, a researcher at the Ikan Medical College of Sinai Medical College in New York City, suggested that it is necessary to effectively defend different varieties of strains, and it may develop a vaccine for certain or more variants.

However, a number of experts pointed out that compared with the existing coronary vaccine, the improved vaccine for the Omikon strain is small.The Garcia -Sastre also said that after the vaccine of specific strains, the new variant virus may have appeared.

WHO recommends adjusting the vaccine formula for the Omikon variants

In addition, the World Health Organization Corporation Vaccine Component Technology Consulting Group said on Friday that the vaccine formula can be adjusted for the Omikon variants, and the public is vaccinated as an additional agent to strengthen resistance.People who have inoculated the basic vaccine series may benefit.

Improved vaccine must obtain an emergency use approval or passed the rigorous national regulatory department approval before it can be used globally.

Many vaccine manufacturers, including Pfizer and Modner, are developing a new generation of crown vaccine, which can also resist Omikon's variants and primitive strains at the same time.

Modner revealed last week that the new version of the company produced can produce a better immune response compared to the original vaccine.The European Drug Administration has begun rolling censorship on the adjustment of the adjustment of Pfizer and Modner.